NeuroSense Therapeutics Ltd. financial data

Symbol
NRSN, NRSNW on Nasdaq
Industry
Pharmaceutical Preparations
Location
11 Hamenofim St., Building B, Herzliya, Israel
State of incorporation
Israel
Fiscal year end
December 31
Latest financial report
6-K - Q4 2023 - Jun 17, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 15.4M shares
Common Stock, Shares, Outstanding 18.1M shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.21M USD
Assets, Current 1.62M USD
Property, Plant and Equipment, Net 77K USD
Operating Lease, Right-of-Use Asset 123K USD
Assets 1.84M USD -76.6%
Employee-related Liabilities, Current 370K USD
Liabilities, Current 3.51M USD
Operating Lease, Liability, Noncurrent 36K USD
Liabilities 3.54M USD -62.4%
Retained Earnings (Accumulated Deficit) -32.4M USD
Stockholders' Equity Attributable to Parent -1.7M USD -234%
Liabilities and Equity 1.84M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 60M shares
Common Stock, Shares, Issued 18.1M shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.21M USD -83%
Deferred Tax Assets, Valuation Allowance 4.76M USD +128%
Operating Lease, Liability 142K USD
Lessee, Operating Lease, Liability, to be Paid 152K USD
Operating Lease, Liability, Current 69K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 78K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 74K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10K USD
Deferred Tax Assets, Operating Loss Carryforwards 3.32M USD +101%
Deferred Tax Assets, Net of Valuation Allowance 4.76M USD +128%